Reviews on Coreg and Pressure on Right Side of Chest

Does Coreg (carvedilol) cause side effects?

Coreg (carvedilol) is a beta-adrenergic blocking amanuensis (beta-blocker) used to treat high blood force per unit area (hypertension), congestive heart failure, and angina (breast hurting from middle illness). Coreg blocks receptors of the adrenergic nervous organisation, the organization of fretfulness in which adrenalin (epinephrine) is active.

Nerves from the adrenergic system enter the heart and release an adrenergic chemical (norepinephrine) that attaches to receptors on the heart's muscle and stimulates the musculus to beat more chop-chop and forcefully. By blocking the receptors, Coreg reduces the eye'southward rate and forcefulness of contraction and thereby reduces the piece of work of the heart.

Coreg also blocks adrenergic receptors on arteries and causes the arteries to relax and the blood pressure to fall. The drop in blood pressure farther reduces the work of the heart since it is easier to pump blood against a lower pressure level.

Mutual side effects of Coreg include

dizziness,
fluid aggregating (edema),
decreased heart rate,
low blood pressure,
weight gain,
diarrhea,
postural hypotension (a rapid subtract in blood pressure level when going from the seated to the continuing position that causes lightheadedness and/or fainting), and
vision abnormalities.

Serious side effects of Coreg include

lightheadedness,
irregular centre rhythm,
common cold feeling or numbness in fingers or toes,
chest pain,
dry coughing,
wheezing,
chest tightness,
heart problems, and
increased blood glucose levels (hyperglycemia).

Drug interactions of Coreg include medications that lower blood sugar such as insulin or oral anti-diabetic medications, because Coreg tin mask early warning symptoms of low blood saccharide (hypoglycemia) such as tremors and increased eye charge per unit.

Patients with diabetes taking medications that lower blood sugar may need to monitor their blood sugar more often. Coreg taken with calcium channel blockers (CCBs) such every bit diltiazem or verapamil may trigger an irregular heart rhythm or an increment in claret pressure.
Reserpine, monoamine oxidase inhibitors, and clonidine, because they have similar mechanisms of activeness equally Coreg, may greatly accentuate the effects of Coreg and cause a steep refuse in blood pressure and/or heart rate.
Close monitoring of claret force per unit area and heart rate may exist needed.
Coreg may cause an increase in digoxin blood levels. Digoxin blood levels should be monitored if Coreg is started, adjusted, or discontinued. Rifampin can sharply decrease the Coreg blood level and in patients taking rifampin, the dose of Coreg may need to exist increased.
Coreg shares a common pathway for elimination by the liver with several other drugs such as quinidine, fluoxetine, paroxetine, or propafenone. Employ of these drugs may block the elimination of Coreg.
Coreg blood levels may be increased (along with the risk for Coreg'south side effects) if patients are taking any of these drugs.
Coreg may increase cyclosporin blood levels. The dose of cyclosporin may need to exist adjusted when the two drugs are used together.
Amiodarone may increase Coreg levels in the blood, increasing the furnishings and potential for toxicity of Coreg.

Prophylactic utilise of Coreg during pregnancy has not been established. No studies with Coreg are available in nursing mothers; withal, use of Coreg while breastfeeding is not recommended due to the risk of a wearisome center rate in the infant.

What are the important side effects of Coreg (carvedilol)?

The most common side effects of carvedilol are:

Dizziness
Edema (fluid accumulation)
Decreased heart rate
Low blood pressure level
Weight gain
increased claret glucose levels (hyperglycemia)
Diarrhea

Postural hypotension (a rapid decrease in blood pressure level when going from the seated to the standing position that causes lightheadedness and/or fainting). Taking carvedilol with food minimizes the risk of postural hypotension.

Other common side effects of carvedilol are an irregular heart rhythm and vision abnormalities.

Carvedilol should be used cautiously in patients who use diuretics or who are elderly or that have:

Cirrhosis
Asthma
Peripheral vascular affliction
Hyperthyroidism
Prinzmetal's variant angina (angina at rest)
Kidney disease.

Coreg (carvedilol) side effects list for healthcare professionals

Clinical Studies Experience

Because clinical trials are conducted under widely varying weather, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reverberate the rates observed in practice.

Coreg has been evaluated for prophylactic in subjects with heart failure (mild, moderate, and severe), in subjects with left ventricular dysfunction post-obit myocardial infarction and in hypertensive subjects.
The observed adverse event profile was consistent with the pharmacology of the drug and the health status of the subjects in the clinical trials.
Adverse events reported for each of these patient populations are provided below.
Excluded are agin events considered too full general to exist informative, and those not reasonably associated with the use of the drug considering they were associated with the condition being treated or are very common in the treated population.
Rates of adverse events were mostly similar across demographic subsets (men and women, elderly and non-elderly, blacks and non-blacks).

Heart Failure

Coreg has been evaluated for condom in heart failure in more than than 4,500 subjects worldwide of whom more 2,100 participated in placebo-controlled clinical trials.
Approximately 60% of the total treated population in placebo-controlled clinical trials received Coreg for at to the lowest degree vi months and thirty% received Coreg for at to the lowest degree 12 months. In the COMET trial, ane,511 subjects with balmy-to-moderate heart failure were treated with Coreg for upwardly to v.9 years (hateful: four.8 years).
Both in U.S. clinical trials in balmy-to-moderate heart failure that compared Coreg in daily doses up to 100 mg (due north = 765) with placebo (north = 437), and in a multinational clinical trial in severe heart failure (COPERNICUS) that compared Coreg in daily doses up to l mg (north = 1,156) with placebo (n = 1,133), discontinuation rates for adverse experiences were similar in carvedilol and placebo subjects.
In placebo-controlled clinical trials, the only cause of discontinuation greater than one% and occurring more oft on carvedilol was dizziness (ane.3% on carvedilol, 0.half dozen% on placebo in the COPERNICUS trial).
Table one shows adverse events reported in subjects with mild-to-moderate heart failure enrolled in U.S. placebo-controlled clinical trials, and with severe eye failure enrolled in the COPERNICUS trial.
Shown are adverse events that occurred more frequently in drug-treated subjects than placebo-treated subjects with an incidence of greater than 3% in subjects treated with carvedilol regardless of causality.
Median trial medication exposure was 6.3 months for both carvedilol and placebo subjects in the trials of mild-to-moderate heart failure and ten.4 months in the trial of subjects with astringent heart failure.
The adverse event profile of Coreg observed in the long-term COMET trial was generally similar to that observed in the U.S. Middle Failure Trials.

Table 1. Adverse Events (%) Occurring More than Oftentimes with Coreg than with Placebo in Subjects with Mild-to-Moderate Centre Failure (HF) Enrolled in U.S. Heart Failure Trials or in Subjects with Severe Heart Failure in the COPERNICUS Trial (Incidence >3% in Subjects Treated with Carvedilol, Regardless of Causality)

Body Arrangement/ Agin Event	Balmy-to-Moderate HF		Severe HF
Body Arrangement/ Agin Event	Coreg (n = 765)	Placebo (n = 437)	Coreg (due north = 1,156)	Placebo (northward = ane,133)
Body as a Whole
Asthenia	7	seven	11	ix
Fatigue	24	22	-	-
Digoxin level increased	5	4	2	one
Edema generalized	v	3	6	5
Edema dependent	iv	2	-	-
Cardiovascular
Bradycardia	9	1	10	three
Hypotension	9	3	fourteen	eight
Syncope	iii	3	viii	5
Angina pectoris	2	3	6	iv
Primal Nervous System
Dizziness	32	19	24	17
Headache	8	7	5	3
Gastrointestinal
Diarrhea	12	vi	v	3
Nausea	nine	5	4	three
Airsickness	6	four	i	2
Metabolic
Hyperglycemia	12	8	5	3
Weight increment	ten	vii	12	11
BUN increased	6	5	-	-
NPN increased	vi	5	-	-
Hypercholesterolemia	4	3	1	1
Edema peripheral	2	i	7	half dozen
Musculoskeletal
Arthralgia	half-dozen	5	1	i
Respiratory
Cough increased	viii	9	5	iv
Rales	4	4	4	2
Vision
Vision abnormal	five	ii	-	-

Cardiac failure and dyspnea were also reported in these trials, but the rates were equal or greater in subjects who received placebo.

The following adverse events were reported with a frequency of greater than 1% only less than or equal to 3% and more frequently with Coreg in either the U.S. placebo-controlled trials in subjects with mild-to-moderate middle failure or in subjects with severe heart failure in the COPERNICUS trial.

Incidence Greater Than 1% To Less Than Or Equal To iii%

Body as a Whole: Allergy, malaise, hypovolemia, fever, leg edema.
Cardiovascular: Fluid overload, postural hypotension, aggravated angina pectoris, AV block, palpitation, hypertension.
Central and Peripheral Nervous System: Hypesthesia, vertigo, paresthesia.
Gastrointestinal: Melena, periodontitis.
Liver and Biliary Arrangement: SGPT increased, SGOT increased.
Metabolic and Nutritional: Hyperuricemia, hypoglycemia, hyponatremia, increased alkaline phosphatase, glycosuria, hypervolemia, diabetes mellitus, GGT increased, weight loss, hyperkalemia, creatinine increased.
Musculoskeletal: Muscle cramps.
Platelet, Bleeding, and Clotting: Prothrombin decreased, purpura, thrombocytopenia.
Psychiatric: Somnolence.
Reproductive, male: Impotence.
Special Senses: Blurred vision.
Urinary Arrangement: Renal insufficiency, albuminuria, hematuria.

Left Ventricular Dysfunction Following Myocardial Infarction

Coreg has been evaluated for prophylactic in survivors of an acute myocardial infarction with left ventricular dysfunction in the CAPRICORN trial which involved 969 subjects who received Coreg and 980 who received placebo.
Approximately 75% of the subjects received Coreg for at least 6 months and 53% received Coreg for at least 12 months.
Subjects were treated for an boilerplate of 12.9 months and 12.8 months with Coreg and placebo, respectively.
The most common adverse events reported with Coreg in the CAPRICORN trial were consequent with the contour of the drug in the U.South. heart failure trials and the COPERNICUS trial.
The just additional adverse events reported in CAPRICORN in greater than iii% of the subjects and more usually on carvedilol were dyspnea, anemia, and lung edema.
The post-obit agin events were reported with a frequency of greater than 1% merely less than or equal to 3% and more than frequently with Coreg:
- flu syndrome,
- cerebrovascular blow,
- peripheral vascular disorder,
- hypotonia,
- depression,
- gastrointestinal pain,
- arthritis, and
- gout.
The overall rates of discontinuations due to adverse events were similar in both groups of subjects.
In this database, the but cause of discontinuation greater than one% and occurring more oftentimes on carvedilol was hypotension (1.5% on carvedilol, 0.2% on placebo).

Hypertension

Coreg has been evaluated for safety in hypertension in more than than 2,193 subjects in U.Southward. clinical trials and in ii,976 subjects in international clinical trials.
Approximately 36% of the total treated population received Coreg for at least 6 months.
Most agin events reported during therapy with Coreg were of mild to moderate severity.
In U.S. controlled clinical trials directly comparison Coreg in doses upwardly to 50 mg (n = 1,142) with placebo (n = 462), iv.9% of subjects receiving Coreg discontinued for adverse events versus v.2% of placebo subjects.
Although in that location was no overall difference in discontinuation rates, discontinuations were more common in the carvedilol group for postural hypotension (1% versus 0).
The overall incidence of adverse events in U.Due south. placebo-controlled trials increased with increasing dose of Coreg.
For individual adverse events this could only exist distinguished for dizziness, which increased in frequency from two% to 5% as full daily dose increased from half-dozen.25 mg to 50 mg.
Tabular array two shows agin events in U.Due south. placebo-controlled clinical trials for hypertension that occurred with an incidence of greater than or equal to ane% regardless of causality and that were more than frequent in drug-treated subjects than placebo-treated subjects.

Table 2. Adverse Events (%) Occurring in U.South. Placebo-Controlled Hypertension Trials (Incidence ≥1%, Regardless of Causality)^a

Body Organisation/ Agin Outcome	Coreg (n = 1,142)	Placebo (n = 462)
Cardiovascular
Bradycardia	2	-
Postural hypotension	2	-
Peripheral edema	i	-
Fundamental Nervous Arrangement
Dizziness	six	5
Insomnia	ii	1
Gastrointestinal
Diarrhea	ii	1
Hematologic
Thrombocytopenia	1	-
Metabolic
Hypertriglyceridemia	1	-
^a Shown are events with charge per unit >1% rounded to nearest integer.

Dyspnea and fatigue were besides reported in these trials, simply the rates were equal or greater in subjects who received placebo.

The post-obit adverse events not described above were reported as possibly or probably related to Coreg in worldwide open or controlled trials with Coreg in subjects with hypertension or heart failure.

Incidence Greater Than 0.one% To Less Than Or Equal To i%

Cardiovascular: Peripheral ischemia, tachycardia.
Key and Peripheral Nervous Systechiliad: Hypokinesia.
Gastrointestinal: Bilirubinemia, increased hepatic enzymes (0.ii% of hypertension patients and 0.4% of heart failure patients were discontinued from therapy because of increases in hepatic enzymes) [meet Postmarketing Feel].
Psychiatric: Nervousness, sleep disorder, aggravated depression, impaired concentration, aberrant thinking, paroniria, emotional lability.
Respiratory Organisation: Asthma [see CONTRAINDICATIONS].
Reproductive, male person: Decreased libido.
Skin and Appendages: Pruritus, rash erythematous, rash maculopapular, rash psoriaform, photosensitivity reaction.
Special Senses: Tinnitus.
Urinary System: Micturition frequency increased.
Autonomic Nervous System: Dry out mouth, sweating increased.
Metabolic and Nutritional: Hypokalemia, hypertriglyceridemia.
Hematologic: Anemia, leukopenia.

The following events were reported in less than or equal to 0.1% of subjects and are potentially of import:

consummate AV block,
bundle co-operative cake,
myocardial ischemia,
cerebrovascular disorder,
convulsions,
migraine,
neuralgia,
paresis,
anaphylactoid reaction,
alopecia,
exfoliative dermatitis,
amnesia,
GI hemorrhage,
bronchospasm,
pulmonary edema,
decreased hearing,
respiratory alkalosis,
increased BUN,
decreased HDL,
pancytopenia, and
atypical lymphocytes.

Laboratory Abnormalities

Reversible elevations in serum transaminases (ALT or AST) have been observed during treatment with Coreg. Rates of transaminase elevations (2 to 3 times the upper limit of normal) observed during controlled clinical trials have mostly been like between subjects treated with Coreg and those treated with placebo.
However, transaminase elevations, confirmed past rechallenge, take been observed with Coreg. In a long-term, placebo-controlled trial in severe heart failure, subjects treated with Coreg had lower values for hepatic transaminases than subjects treated with placebo, possibly because improvements in cardiac function induced by Coreg led to less hepatic congestion and/or improved hepatic claret flow.
Coreg has not been associated with clinically significant changes in serum potassium, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea nitrogen, or creatinine.
No clinically relevant changes were noted in fasting serum glucose in hypertensive patients; fasting serum glucose was not evaluated in the eye failure clinical trials.

Postmarketing Experience

The post-obit adverse reactions take been identified during post-approval employ of Coreg. Considering these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood And Lymphatic System Disorders

Aplastic anemia.

Immune System Disorders

Hypersensitivity (east.g., anaphylactic reactions, angioedema, urticaria).

Renal And Urinary Disorders

Urinary incontinence.

Respiratory, Thoracic, And Mediastinal Disorders

Interstitial pneumonitis.

Skin And Subcutaneous Tissue Disorders

Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.

What drugs interact with Coreg (carvedilol)?

CYP2D6 Inhibitors And Poor Metabolizers

Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, merely these drugs would be expected to increment blood levels of the R(+) enantiomer of carvedilol.
Retrospective assay of side effects in clinical trials showed that poor 2D6 metabolizers had a college charge per unit of dizziness during upwardly-titration, presumably resulting from vasodilating effects of the higher concentrations of the α-blocking R(+) enantiomer.

Hypotensive Agents

Patients taking a β-blocker and a drug that tin deplete catecholamines (e.one thousand., reserpine and monoamine oxidase inhibitors) should exist observed closely for signs of hypotension and/or severe bradycardia.
Concomitant administration of clonidine with a β-blocker may cause hypotension and bradycardia.
When concomitant handling with a β-blocker and clonidine is to exist terminated, the β-blocker should be discontinued offset. Clonidine therapy can then be discontinued several days afterwards by gradually decreasing the dosage.

Cyclosporine

Modest increases in mean trough cyclosporine concentrations were observed post-obit initiation of carvedilol handling in 21 renal transplant subjects suffering from chronic vascular rejection.
In nigh xxx% of subjects, the dose of cyclosporine had to be reduced in society to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.
On the boilerplate for the grouping, the dose of cyclosporine was reduced about 20% in these subjects.
Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely later initiation of carvedilol therapy and that the dose of cyclosporine be adjusted equally appropriate.

Digitalis Glycosides

Both digitalis glycosides and β-blockers deadening atrioventricular conduction and decrease heart charge per unit.
Concomitant utilize can increase the chance of bradycardia. Digoxin concentrations are increased past nigh 15% when digoxin and carvedilol are administered concomitantly. Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing Coreg.

Inducers/Inhibitors Of Hepatic Metabolism

Rifampin reduced plasma concentrations of carvedilol past about 70%. Cimetidine increased AUC by about 30% merely acquired no modify in Cmax.

Amiodarone

Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P-glycoprotein increased concentrations of the South(-)-enantiomer of carvedilol by at least ii fold.
The concomitant administration of amiodarone or other CYP2C9 inhibitors such equally fluconazole with Coreg may enhance the β-blocking activity, resulting in further slowing of the eye rate or cardiac conduction.
Patients should exist observed for signs of bradycardia or heart block, particularly when 1 agent is added to pre-existing handling with the other.

Calcium Channel Blockers

Conduction disturbance (rarely with hemodynamic compromise) has been observed when Coreg is coadministered with diltiazem.
As with other β-blockers, if Coreg is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and claret pressure be monitored.

Insulin Or Oral Hypoglycemics

β-blockers may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics. Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended.

Anesthesia

If treatment with Coreg is to be continued perioperatively, item care should be taken when coldhearted agents that depress myocardial function, such every bit ether, cyclopropane, and trichloroethylene, are used.

Summary

Coreg (carvedilol) is a beta-adrenergic blocking agent (beta-blocker) used to treat loftier blood pressure (hypertension), congestive heart failure, and angina (chest pain from middle disease). Common side effects of Coreg include dizziness, fluid accumulation (edema), decreased heart charge per unit, low blood force per unit area, weight gain, diarrhea, postural hypotension (a rapid decrease in claret pressure when going from the seated to the standing position that causes lightheadedness and/or fainting), and vision abnormalities. Safe apply of Coreg during pregnancy has not been established. No studies with Coreg are bachelor in nursing mothers; nonetheless, use of Coreg while breastfeeding is non recommended due to the risk of a wearisome heart rate in the infant.

Multimedia: Slideshows, Images & Quizzes

Related Disease Atmospheric condition

High Blood Pressure (Hypertension)

Loftier blood pressure (hypertension) is a disease in which pressure within the arteries of the body is elevated. Most 75 million people in the U.s.a. have hypertension (1 in three adults), and only half of them are able to manage it. Many people practise not know that they have loftier blood pressure because it often has no has no warning signs or symptoms. Systolic and diastolic are the two readings in which blood force per unit area is measured. The American College of Cardiology released new guidelines for loftier blood pressure in 2017. The guidelines at present state that blood normal claret pressure level is 120/80 mmHg. If either ane of those numbers is higher, you have high claret force per unit area. The American Academy of Cardiology defines loftier blood pressure slightly differently. The AAC considers 130/80 mm Hg. or greater (either number) stage 1 hypertension. Phase two hypertension is considered 140/90 mm Hg. or greater. If you take loftier claret pressure level you are at risk of developing life threatening diseases like stroke and centre attack.REFERENCE: CDC. High Blood Pressure level. Updated: November thirteen, 2017.
Hypertension-Related Kidney Disease

Second Source WebMD Medical Reference
High Blood Pressure Treatment (Natural Home Remedies, Diet, Medications)

High blood pressure (hypertension) means high pressure level (tension) in the arteries. Treatment for high blood force per unit area include lifestyle modifications (booze, smoking, coffee, salt, nutrition, exercise), drugs and medications such equally ACE inhibitors, angiotensin receptor blockers, beta blockers, diuretics, calcium channel blockers (CCBs), alpha blockers, clonidine, minoxidil, and Exforge.
Portal Hypertension

Portal hypertension is most commonly acquired by cirrhosis, a disease that results from scarring of the liver. Other causes of portal hypertension include claret clots in the portal vein, blockages of the veins that conduct the blood from the liver to the center, and a parasitic infection called schistosomiasis. Symptoms of portal hypertension include varices (enlarged veins), vomiting blood, blood in the stool, black and tarry stool, ascites (abnormal fluid collection within the peritoneum, the sac that contains the intestines within the abdominal cavity), confusion and sluggishness, splenomegaly or enlargement of the spleen, and decreased white blood jail cell counts.
Hypertensive Kidney Illness

High claret pressure can damage the kidneys and is one of the leading causes of kidney failure (stop-stage renal kidney disease). Kidney damage, like hypertension, can be unnoticeable and detected only through medical tests. If you have kidney disease, you should control your blood pressure level. Other treatment options include prescription medications.
Pulmonary Hypertension

Pulmonary hypertension is elevated pressure in the pulmonary arteries that carry blood from the lungs to the centre. The almost common symptoms are fatigue and difficulty breathing. If the condition goes undiagnosed, more severe symptoms may occur. As pulmonary hypertension worsens, some people with the condition have difficulty performing whatever activities that require concrete exertion. While there is no cure for pulmonary hypertension, information technology can be managed and treated with medications and supplemental oxygen to increase blood oxygen levels.
Tin High Blood Pressure Hurt My Eyes?

Unfortunately, yes. Suffering from untreated or poorly controlled loftier blood force per unit area for a long fourth dimension can exist detrimental to your eyes. Several middle diseases are directly or indirectly caused by loftier blood force per unit area (hypertension).
Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)

Pseudotumor Cerebri (intracranial hypertension) is a status where at that place is an increment in pressure of fluid surrounding the encephalon and spinal cord (cerebrospinal fluid or CSF) mimicing a brain tumor. The cause is unknown. The almost common symptom is headache but likewise include eye-pain, vision loss and double vision. Pseudotumor cerebri is diagnosed with MRI or True cat scans and treated by discontinuing offending medications (if applicative), weight loss and diuretic medications. The condition can as well be helped by repeated drainage of spinal fluid using the lumbar puncture.
Preeclampsia (Pregnancy Induced Hypertension)

Preeclampsia is related to increased blood pressure and protein in the mother'southward urine. Preeclampsia typically begins after the 20th week of pregnancy. When preeclampsia causes seizures, it is termed "eclampsia" and is the second leading cause of maternal decease of in the US. Preeclampsia is the leading crusade of fetal complications. Gamble factors for preeclampsia include high blood force per unit area, obesity, multiple births, and women with preexisting medical conditions such as diabetes, kidney illness, rheumatoid arthritis, lupus, or scleroderma. Pregnancy planning and lifestyle changes may reduce the risk of preeclampsia during pregnancy.
High Claret Pressure Symptoms

Most people with high claret pressure have no signs or symptoms, fifty-fifty if blood pressure readings reach dangerously high levels. In some patients, symptoms may include fatigue, headaches, dizziness, confusion, sweating, chest pain and vision problems.
What Is High Claret Pressure (Hypertension)?

Loftier blood pressure level or hypertension is when the blood force per unit area readings consistently range from 140 or higher for systolic or 90 or higher for diastolic. Blood pressure readings above 180/120 mmHg are dangerously high and require immediate medical attending.
How Does High Blood Force per unit area Affect Pregnancy?

High blood pressure during pregnancy can cause serious complications. Acquire more about the signs of and risks associated with the condition.
Hypertension-Induced Chronic Kidney Disease

Hypertension-induced chronic kidney disease (CKD) is a long-continuing kidney condition that develops over time due to persistent or uncontrolled high blood pressure (hypertension).